Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans (ALLOPIV)

Assistance Publique - Hôpitaux de Paris

Status

Enrolling

Conditions

Acute Respiratory Infection

Allogeneic Hematopoietic Stem Cell Recipients

Parainfluenza Virus (PIV)

Treatments

Other: samples

Study type

Observational

Funder types

Other

Identifiers

NCT04099082

APHP180175

Details and patient eligibility

About

Bronchiolitis obliterans (BO) is the well-known manifestation of the chronic pulmonary graft-versus-host disease(GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). The pathophysiology of BO is, however, poorly known. The available data strongly support the role of respiratory viruses, in particular paramyxoviruses (parainfluenzae virus (PIV), respiratory syncytial virus, metapneumovirus). It is likely that the alloimmune response triggered by the respiratory virus is inadequate and leads to the peribronchiolar fibrotic process. The objective is to analyze the kinetics of profiles of the blood and respiratory host responses resulting from a high or low parainfluenza respiratory infection, in order to evaluate if the occurrence of a BO is associated with a specific signature We will evaluate the predictive signature of a BO after a parainfluenza virus infection by characterizing the differences between the patients evolving and those not evolving to a BO at 2 months after the infection.

Enrollment

14 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria :

Adults having received a hematopoietic stem cell transplantation for less than two years
Availability of respiratory function tests prior to infection
Presence of PIV respiratory infection documented by identification of the virus by PCR in the upper and/or lower respiratory tract
Symptoms of respiratory infection ≤ 5 days
Signed informed consent

Exclusion Criteria:

Presence of a respiratory virus infection other than PIV
Viral respiratory co-infections
Bacterial or fungal respiratory infections
Treatment with ribavirin, oseltamivir or any other antiviral with activity against respiratory viruses
Patient not affiliated or beneficiary of a social security system
Patient deprived of liberty or protected
Pregnant or breastfeeding woman